-
Mashup Score: 2HMAs Are ‘Cornerstone’ in High-risk MDS Treatment Says Jamile Shammo, MD | Blood Cancers Today - 5 day(s) ago
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1How COVID-19 Helped Me Cope Day to Day With Cancer - 6 day(s) ago
I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 2HMAs Are ‘Cornerstone’ in High-risk MDS Treatment Says Jamile Shammo, MD | Blood Cancers Today - 8 day(s) ago
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2HMAs Are ‘Cornerstone’ in High-risk MDS Treatment Says Jamile Shammo, MD | Blood Cancers Today - 8 day(s) ago
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Durable Transfusion Independence in Lower-Risk MDS - 9 day(s) ago
Gary J. Schiller, MD, reviews recent data on durable transfusion independence for patients with lower-risk MDS in the IMerge phase 3 study and discusses how transfusion frequency affects patient outcomes.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Choosing Treatment for Lower-Risk MDS - 10 day(s) ago
Experts comment on factors that influence their decision-making when treating patients with lower-risk MDS.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Addressing MDS Treatment Gap Post Hypomethylating Failure - 27 day(s) ago
The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Aditi Shastri, MD: Clinicians Needs to ‘Come Together’ on TP53-Mutated MDS | Blood Cancers Today - 27 day(s) ago
Using the VALIDATE database, researchers looked at treatment response to HMAs and overall survival in patients with TP53-mutated MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
This early analysis suggests that the combination of oral decitabine plus cedazuridine with venetoclax for higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia is safe in most patients, with encouraging activity. Longer follow-up will be needed to confirm these data.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
🚨 Out now! 🚨 On this week's episode of “The HemOnc Pulse,” Jamile Shammo, MD, of @NorthwesternU, joins host @chadinabhan to discuss how to approach treatment for #MDS, including treating patients with ESAs or HMAs. 🎧 Listen here! https://t.co/7yYTJPa3us https://t.co/JqFuBjgodx